Baseline results from the UK SIGNIFY study: a whole-body MRI screening study in TP53 mutation carriers and matched controls
Sibel Saya, Emma Killick, Sarah Thomas, Natalie Taylor, Elizabeth K Bancroft, Jeanette Rothwell, Sarah Benafif, Alexander Dias, Christos Mikropoulos, Jenny Pope, Anthony Chamberlain, Ranga Gunapala, Louise Izatt, Lucy Side, Lisa Walker, Susan Tomkins, Jackie Cook, Julian Barwell, Vicki Wiles, Lauren Limb Show all
FAMILIAL CANCER | SPRINGER | Published : 2017
In the United Kingdom, current screening guidelines for TP53 germline mutation carriers solely recommends annual breast MRI, despite the wide spectrum of malignancies typically seen in this group. This study sought to investigate the role of one-off non-contrast whole-body MRI (WB MRI) in the screening of asymptomatic TP53 mutation carriers. 44 TP53 mutation carriers and 44 population controls were recruited. Scans were read by radiologists blinded to participant carrier status. The incidence of malignancies diagnosed in TP53 mutation carriers against general population controls was calculated. The incidences of non-malignant relevant disease and irrelevant disease were measured, as well as ..View full abstract
Awarded by Cancer Research UK
Awarded by National Institute for Health Research
We thank all the participants and families who took part in this research. This work was supported by The Annabel Evens Memorial Fund. The investigators at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust are supported by an NIHR research grant to the Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust. The SIGNIFY Study Steering Committee: Prof Anwar Padhani, Paul Strickland Scanner Centre, Mount Vernon Cancer Centre; Prof Leslie Walker, University of Hull; Dr Gillian Mitchell, Familial Cancer Centre, Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, University of Melbourne; Dr Gek Kwan-Lim, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust; Susan Eastbrook, patient representative; Dr Peter Simmonds, Cancer Sciences Academic Unit and University of Southampton Clinical Trials Unit, Faculty of Medicine, University of Southampton and University Hospital Southampton Foundation Trust; Dr Frank Saran, The Royal Marsden NHS Foundation Trust.